title: Ganglion Cell Complex Evaluation in Exudative Age-Related Macular Degeneration after Repeated Intravitreal Injections of Ranibizumab.
abstract: Purpose. To detect the effects of intravitreal ranibizumab injections on GCC in patients with wet AMD. Methods. 32 wet AMD eyes were selected and submitted at three ranibizumab injections. RTVue-OCT GCC and MM5 protocol were performed before treatment and twenty days after each injection. Results. At baseline mean GCC thickness was 93.9 ± 18.5 μm. Twenty days after each intravitreal injection it was, respectively, 85.8 ± 10.1, 86.5 ± 9.3, and 91.1 ± 11.5 μm, without statistical significance. A significant improvement in visual acuity (P = 0.031) and a reduction of mean foveal (P = 0.001) and macular thickness (P = 0.001) were observed. Conclusion. The clinical results confirm therapeutic efficacy of intravitreal injections of ranibizumab in wet AMD. A contemporary not statistically significant reduction of GCC thickness suggests that the loading phase of ranibizumab does not have any toxic effects on ganglion cell complex.
authors.affiliation: Ophthalmology Unit, NESMOS Department, Sant'Andrea Hospital, Faculty of Medicine and Psychology, "Sapienza" University of Rome, Via di Grottarossa 1035-1039, 00189 Rome, Italy.
authors.forename: Andrea
authors.initials: A
authors.lastname: Perdicchi
authors.affiliation: Ophthalmology Unit, NESMOS Department, Sant'Andrea Hospital, Faculty of Medicine and Psychology, "Sapienza" University of Rome, Via di Grottarossa 1035-1039, 00189 Rome, Italy.
authors.forename: Giacomo
authors.initials: G
authors.lastname: Peluso
authors.affiliation: Ophthalmology Unit, NESMOS Department, Sant'Andrea Hospital, Faculty of Medicine and Psychology, "Sapienza" University of Rome, Via di Grottarossa 1035-1039, 00189 Rome, Italy.
authors.forename: Daniela
authors.initials: D
authors.lastname: Iacovello
authors.affiliation: Ophthalmology Unit, NESMOS Department, Sant'Andrea Hospital, Faculty of Medicine and Psychology, "Sapienza" University of Rome, Via di Grottarossa 1035-1039, 00189 Rome, Italy.
authors.forename: Marco
authors.initials: M
authors.lastname: Balestrieri
authors.affiliation: Ophthalmology Unit, NESMOS Department, Sant'Andrea Hospital, Faculty of Medicine and Psychology, "Sapienza" University of Rome, Via di Grottarossa 1035-1039, 00189 Rome, Italy.
authors.forename: Martina
authors.initials: M
authors.lastname: Delle Fave
authors.affiliation: Ophthalmology Unit, Azienda Policlinico Umberto I, "Sapienza" University of Rome, Viale del Policlinico 155, 00186 Rome, Italy.
authors.forename: Solmaz
authors.initials: S
authors.lastname: Abdolrahimzadeh
authors.affiliation: Ophthalmology Unit, NESMOS Department, Sant'Andrea Hospital, Faculty of Medicine and Psychology, "Sapienza" University of Rome, Via di Grottarossa 1035-1039, 00189 Rome, Italy.
authors.forename: Gian Luca
authors.initials: GL
authors.lastname: Scuderi
authors.affiliation: Ophthalmology Unit, NESMOS Department, Sant'Andrea Hospital, Faculty of Medicine and Psychology, "Sapienza" University of Rome, Via di Grottarossa 1035-1039, 00189 Rome, Italy.
authors.forename: Vito
authors.initials: V
authors.lastname: Fenicia
authors.affiliation: Ophthalmology Unit, NESMOS Department, Sant'Andrea Hospital, Faculty of Medicine and Psychology, "Sapienza" University of Rome, Via di Grottarossa 1035-1039, 00189 Rome, Italy.
authors.forename: Santi Maria
authors.initials: SM
authors.lastname: Recupero
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D058449:Intravitreal Injections; D008297:Male; D000069579:Ranibizumab / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D012165:Retinal Ganglion Cells / Q000187:drug effects / Q000473:pathology*; D016896:Treatment Outcome; D014792:Visual Acuity / Q000187:drug effects; D057135:Wet Macular Degeneration / Q000188:drug therapy* / Q000473:pathology* / Q000503:physiopathology
chemical_list: D020533:Angiogenesis Inhibitors; D000069579:Ranibizumab